Original papers

1. Rigas B. The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Curr Opin Gastroenterol. 2007 Jan;23(1):55-9.
2. Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, Patlolla JM, Simi B, Kopelovich L, Rigas B. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther. 2006 Jun;5(6):1530-8.
3. Iconomou G, Kalofonos HP, Koutras AK, Vagenakis AG, Rigas B. Pilot study of nitric oxide-donating aspirin in patients with pancreatic cancer pain. J Support Oncol. 2006 Apr;4(4):168.
4. Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, Kashfi K, Rigas B. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 2006 Apr 15;66(8):4503-11.
5. Muscat JE, Dyer AM, Rosenbaum RE., Rigas B. Nitric oxide-releasing medications and colorectal cancer risk: the framingham study. Anticancer Res. 2005 Nov-Dec;25(6C):4471-4.
6. Gao J, Liu X, Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci USA, 2005 Nov 22;102(47):17207-12.
7. Gao J, Kashfi K, Liu X, Rigas B. NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis. 2006 Apr;27(4):803-10.
8. Hundley TR, Rigas B. Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J Pharmacol Exp Ther. 2006 Jan;316(1):25-34.
9. Ouyang N, Williams JL, Rigas B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis. Carcinogenesis. 2006 Feb;27(2):232-9.
10. Spiegel A, Hundley TR, Chen J, Gao J, Ouyang N, Liu X, Go MF, Tsioulias GJ, Kashfi K, Rigas B. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochem Pharmacol. 2005 Oct 1;70(7):993-1000.
11. Rigas B, Kashfi K. Cancer prevention: a new era beyond cyclooxygenase-2. J Pharmacol Exp Ther. 2005 Jul;314(1):1-8.
12. Nath N, Labaze G, Rigas B, Kashfi K. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression. Biochem Biophys Res Commun. 2005 Jan 7;326(1):93-9.
13. Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, Benedini F, Del Soldato P, Rigas B. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther. 2005 Mar;312(3):978-88.

14. Gao J, Kashfi K, Rigas B. In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. J Pharmacol Exp Ther. 2005 Mar;312(3):989-97.

Chapters, Reviews and Editorials

Zhang Z, Rigas B. NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review) Int J Oncol. 2006 Jul;29(1):185-92. Review.

Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol. 2005 Oct 1;70(7):969-86. Review.




Rigas B, Kashfi K. Nitric oxide–donating NSAIDs as agents for cancer prevention. Trend Molec Med 2004, 10:324-30.

Rigas B, Kalofonos H, Lebovics E, Vagenakis AG. NO-NSAIDs and cancer: Potential applications. Dig Liver Dis, 2003; 35 Suppl 2:S27-34.

Komninou D, AyonoteA, Richie JrJ, Rigas B. Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med, 2003; 228:396-405.

Rigas B, Williams JL. NO-releasing NSAIDs and colon cancer chemoprevention: A promising novel approach. Int J Oncol, 2002; 20:885-90.

7. Rigas B. The prevention of colon cancer. Leader for CHEMIST, 2002; 4:4-11 (in both Italian and English).

8. Rayyan Y, Williams JL, Rigas B. The role of NSAIDs in the prevention of cancer. Cancer Invest, 2002;20:1002-1011.